Diagnostic Performance of EUS ‐ FNA for Pancreatic Lesions at Tertiary Centers in Iran Without Rapid On‐Site Evaluation
Cytopathology · 2025
DOI: 10.1111/cyt.70047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytopathology, 2025. Verfasst von Maryam Bazmandegan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Endoscopic Ultrasound-Guided Fine Needle Aspiration, Pancreatic Neoplasms, Pancreas. Die Arbeit nennt 65 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences.
Abstract (Originalsprache)
Background
Endoscopic ultrasonography‐guided fine needle aspiration (EUS‐FNA) is widely used for diagnosing pancreatic neoplasms, contributing to improved therapeutic strategies for pancreatic cancer. This aim of this study is to evaluate the diagnostic utility, sample adequacy, and limitations of EUS‐FNA cytology for pancreatic lesions. These were further confirmed after surgical resection and histopathological evaluation.
Methods
We retrospectively included patients referred to two Teaching Hospitals in southern Iran for EUS‐FNA due to suspected pancreatic cancer, who later underwent surgical resection or biopsy and eventually had a histopathological confirmed diagnosis. The cytological smears from EUS‐FNA were compared with the final histology reports to assess diagnostic performance.
Results
Thirty patients were included in the final analysis. EUS‐FNA cytology showed sensitivity of 90.00% [95% CI: 68.30, 98.77], specificity of 80.00% [95% CI: 44.39, 97.48], negative predictive value (NPV) of 80.00% [95% CI: 50.89, 93.92], positive predictive value (PPV) of 90.00% [95% CI: 72.09, 96.91], and overall accuracy of 86.67% [95% CI: 69.28, 96.24]. Two false‐positive diagnoses (hydatid cyst and chronic pancreatitis) and two false‐negative diagnoses (malignancies attributed to sampling errors) were observed. Immunohistochemical tests confirmed 8 out of 9 diagnoses made by cytology. Notably, all EUS‐FNA samples provided adequate material for conclusive diagnosis.
Conclusion
These results support the high importance of the diagnostic performance of EUS‐FNA on solid pancreatic lesions, even without Rapid On Site Evaluation (ROSE), given that the sample is of adequate size for testing. Despite a few false negative and false positive diagnoses, EUS‐FNA should be considered the first‐line diagnostic tool for pancreatic lesions assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.
- Gastroenterohepatology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
- Shiraz Transplant Research Center (STRC), Shiraz University of Medical Sciences, Shiraz, Iran.
ORCID-Profile: Zahra Beyzaei, Bita Geramizadeh
Förderung
- Shiraz University of Medical Sciences
Zitieren
APA
Bazmandegan, M., Sivandzadeh, G. R., Lankarani, K. B., Beyzaei, Z., & Geramizadeh, B. (2025). Diagnostic Performance of EUS ‐ FNA for Pancreatic Lesions at Tertiary Centers in Iran Without Rapid On‐Site Evaluation. Cytopathology. https://doi.org/10.1111/cyt.70047
Vancouver
Bazmandegan M, Sivandzadeh GR, Lankarani KB, Beyzaei Z, Geramizadeh B. Diagnostic Performance of EUS ‐ FNA for Pancreatic Lesions at Tertiary Centers in Iran Without Rapid On‐Site Evaluation. Cytopathology. 2025. doi:10.1111/cyt.70047
BibTeX
@article{Bazmandegan2025,
author = {Bazmandegan, Maryam and Sivandzadeh, Gholam Reza and Lankarani, Kamran Bagheri and Beyzaei, Zahra and Geramizadeh, Bita},
title = {Diagnostic Performance of EUS ‐ FNA for Pancreatic Lesions at Tertiary Centers in Iran Without Rapid On‐Site Evaluation},
journal = {Cytopathology},
year = {2025},
doi = {10.1111/cyt.70047}
}
EUVIMED